XIX International AIDS Conference

THSY03 HIV Persistence and Eradication
  Symposia Session
Venue: Session Room 9
Time: 26.07.2012, 11:00 - 12:30
Co-Chairs: Steven G. Deeks, United States
Françoise Barré-Sinoussi, France
This session is directed to clinicians and scientists interested in better understanding the rapid advances in knowledge related to HIV latency, persistence, compartments and therapeutic approaches. With an increasing number of HIV-infected individuals achieving viral control thanks to antiretroviral drugs, the challenge of long-term administration of treatment, currently life-long, including drug toxicity and economic cost, calls for a scientific effort at understanding the principles of viral latency. This session will discuss basic principles of latency and present the advent of new therapeutic concepts. Practical considerations and challenges will also be highlighted. At the completion of the session, participants will be knowledgeable about the key concepts regarding identification of cellular and tissue reservoirs as well as transcriptional control of proviral gene expression. Session participants will also have learnt about therapeutic targeting of the latent reservoir using gene therapy approaches, immunomodulators and new families of purge drugs and the prospects for developing a cure.


The memory cell and the latent virus

V. Planelles, United States

Molecular mechanisms of latency

B. Berkhout, Netherlands

Improving means to activate/eliminate latent HIV reservoirs

J. Zack, United States

Immunopathogenesis and reservoirs

M. Benkirane, France


New frontier in HIV research: the French perspective

G. Fioraso, France


Powerpoints presentations
The memory cell and the latent virus - Vicente Planelles

Rapporteur report

Track A report by Jason Brenchley

The theme of this session was the discussion of mechanisms underlying HIV persistence and novel therapeutic interventions. Dr. Vincent Planelles (University of Utah) discussed memory CD4 T cells as a main source of latent HIV. He presented a model of in vitro differentiation of naïve CD4 T cells into different subsets of memory CD4 T cells with concomitant HIV infection with single cycle virus. Using this model he showed that limiting amounts of cyclin T and phosphorylation of CDK9 decreases HIV transcription in unstimulated memory and naïve CD4 T cells. He was able to use this model to screen putative therapeutics to drive HIV from latent pools. Dr. Benjamin Berkout (University of Amsterdam) used a cell line model of latency to sequence small RNAs  and unexpectedly found antisense strand HIV sequences which could result in double stranded RNA species which decrease HIV transcription. He then discussed in vitro activation of CD4 T cells with immature dendtric cells as a method to drive HIV from latency. This induction of HIV replication from latency involved both cell to cell interactions and soluble factors produced by the dendritic cells. Dr. Jerome Zack (UCLA) discussed methods to activate and eliminate latent HIV reservoirs. He used prostratin or byrostatin as therapies to purge HIV from latency. Using an innovative approach of nanoparticle delivery of these compounds to CD4 T cells, he was able to selectively activate CD4 T cells to increase HIV transcription in vitro. He was able to synthesize cost effective analogs of prostratin and byrostatin which more efficiently increased HIV transcription. Dr. Monsef Benkirane (CNRS) discussed a role for SAMHD1 in the immunopathogenesis and replication of HIV. Even though it is believed that SAMHD1 is thought to restrict HIV predominantly in myeloid cells, he presented data suggesting that SAMHD1 function is also present in resting CD4 T cells and can reduce HIV infection. Introduction of the accessory protein Vpx in trans led to enhanced HIV infection of quiescent CD4 T cells. The French minister of higher education and research closed the session. Geneviève Fioraso discussed the French commitment to HIV research and announced a signed agreement between ANRS and the NIH to increase collaborative research effort. 


    The organizers reserve the right to amend the programme.

Contact Us | Site map © 2012 International AIDS Society